Omega Therapeutics, Inc. (OMGA) Misses Q2 EPS by 4c

Omega Therapeutics, Inc. (NASDAQ: OMGA) reported Q2 EPS of ($0.54), $0.04 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $760 thousand versus the consensus estimate of $378.57 thousand.

For earnings history and earnings-related data on Omega Therapeutics, Inc. (OMGA) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• RBC bullish on Kraft Heinz, sees return to growth in 2027
• The Fed is hiking. Why isn't UBS worried about stocks?